Clinical trials: Cognitive Function Assessment
- Condition Cognitive Function Assessment
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
Chorea, Huntington
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
- Trial name
- KINECT-HD (NCT04102579)
- Testing
- Valbenazine
- Where
- 46 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Neurocrine Biosciences
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Disease
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640.
- Trial name
- NCT00550420
- Testing
- Rosiglitazone XR
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 331 people
- Sponsor
- GlaxoSmithKline
Cognition
A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children
The effect of supplementation using both protein and multiple micronutrients in preschool age children on cognitive performance and growth is unknown.
- Trial name
- NCT02177942
- Testing
- Test beverage powder (High Proteins and added micronutrients), Control beverage powder (Low protein and no added micronutrients)
- Where
- India
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort.
- Trial name
- NCT04437511
- Testing
- Donanemab
- Where
- 274 sites in United States, Australia and 7 more
- Volunteers
- 1,736 people
- Sponsor
- Eli Lilly and Company
Huntington's Disease
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
- Trial name
- NCT01806896
- Testing
- PF-02545920
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Pfizer
Neurogenic Detrusor Overactivity
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
- Trial name
- NCT01565694
- Testing
- Solifenacin succinate
- Where
- 21 sites in United States, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Astellas Pharma Europe B.V.
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Cognitive Decline
Evaluation of Cognitive State in Seniors Using Neurosteer EEG System
This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an…
- Trial name
- NCT05528445
- Testing
- Neurosteer EEG recorder
- Where
- Israel
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Neurosteer Ltd.
Alzheimer's Disease, Dementia
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
This study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00874939
- Testing
- MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cognitive Function
Evaluation of DCTclock™ as a Cognitive Assessment Aid
The overall objective of this study is to demonstrate the safety and effectiveness of DCTclock as an adjunctive tool for use by clinicians to evaluate cognitive function in adults aged 55-95.
- Trial name
- NCT03238001
- Testing
- DCTclock
- Where
- United States
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Digital Cognition Technologies
Alzheimer Disease, Cognitive Dysfunction
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive and neuropsychiatric symptoms in participants with mild cognitive impairment (MCI) or mild dementia due to…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
- Trial name
- NCT04602624
- Testing
- SAGE-718
- Where
- 10 sites in United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Chronic Heart Failure (CHF)
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState…
- Trial name
- PERSPECTIVE (NCT02884206)
- Testing
- LCZ696, Valsartan
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 592 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.
- Trial name
- NCT01161524
- Testing
- Perampanel
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Obsessive Compulsive Disorder
Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
To evaluate the long-term impact of treatment with sertraline on aspects of cognitive, emotional and physical development and pubertal maturation in pediatric subjects ages 6 to 16 years (inclusive) with a diagnosis of anxiety…
- Trial name
- SPRITES (NCT01302080)
- Testing
- sertraline, psychotherapy
- Where
- 44 sites in United States
- Volunteers
- 941 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia
This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia
- Trial name
- NCT01009060
- Testing
- GSK239512
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company